Enovis CORP price to free cash flow ENOV
Market value divided by free cash flow over the last twelve months, since 2016.
- Today, Nov 2, 2026
- 18.7×
- 10-year median
- 17.1×
- Against its 10-year history
- 52nd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 10.5× to 409×
- Peer median
- 16.9×
Enovis CORP's price to free cash flow is 18.7× as of Nov 2, 2026.
That is above its ten-year median of 17.1×, close to the middle of its last ten years.
Over that time it ranged from 10.5× in Feb 2018 to 409× in Feb 2020.
The median for 10 medical instruments and supplies stocks of a similar size is 16.9×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 18.7× | 16.0× | 75.6× |
| 2025 | 68.8× | 66.5× | 76.0× |
| 2024 | 236× | 236× | 269× |
| 2023 | n/m a value too high to mean anything | ||
| 2022 | 58.1× | 12.8× | 69.4× |
| 2021 | 14.5× | 13.9× | 21.0× |
| 2020 | 19.7× | 13.5× | 409× |
| 2019 | 39.9× | 11.2× | 39.9× |
| 2018 | 11.7× | 10.5× | 35.1× |
| 2017 | 12.9× | 11.1× | 16.7× |
| 2016 | 14.5× | 7.1× | 15.8× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Enovis CORP's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| ENOVEnovis CORP | 18.7× |
| STAAStaar Surgical | n/m |
| BVSBioventus | 11.7× |
| IARTIntegra Lifesciences | 12.3× |
| CDRECadre | 17.3× |
| EYENational Vision | 27.6× |
| IRMDIradimed | 38.9× |
| LMATLemaitre Vascular | 25.2× |
| INSPInspire Medical Systems | 16.6× |
| MOVMovado | 10.0× |
| UFPTUFP Technologies | n/m |
| Peer median | 16.9× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Enovis CORP
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.